Where can researchers source third-party tested VIP?

Midwest Peptide supplies research-grade VIP with a Certificate of Analysis included for every batch, validated by HPLC purity and mass spectrometry identity testing.

Age Verification

You must be 21 years or older to access this website. All products are for research use only.

Are you 21 years of age or older?

By entering, you confirm that you are at least 21 years old and agree to our terms of service.

Memorial Day: 15% off code MEMDAY15Memorial Day Sale — 15% off site-wide with code MEMDAY15

Free shipping on every orderFree shipping on every order

5% off with Zelle or Apple CashSave an extra 5% when you pay with Zelle or Apple Cash

Bulk pricing discounts up to 18%Bulk pricing discounts up to 18% off

VIP Neuroinflammation Research Studies | Midwest Peptide

VIP Circadian Research: SCN Pathway Studies in Animal ModelsPrev|VIP Receptor Research: VPAC1 and VPAC2 Signaling in Research ModelsNext

VIP Neuroinflammation Research: Animal Model Studies

Q: Is VIP approved for human use?

No. VIP is not approved by the FDA for any human therapeutic use. It is supplied strictly for in-vitro and preclinical research purposes by qualified investigators.

VIP · Published April 8, 2026 · Updated May 18, 2026 · 7 min read

Quick Answer

VIP neuroinflammation research examines microglial modulation, T cell effects, and cytokine reductions in rodent CNS inflammation models. Studies measure microglial polarization markers, inflammatory cytokines, and neuroprotective biomarkers across standardized neuroinflammation research protocols using vasoactive intestinal peptide. For research use only, not for human consumption.

VIP Neuroinflammation Research: Animal Model Studies

Research Use Only. All products are strictly for research use only (RUO). Not for human consumption. Products on this site are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA. By purchasing, you agree that you are a qualified researcher and that products will be used solely for in-vitro research purposes.

Neuroinflammation as a Research Endpoint
VIP Effects on Microglia
VIP and T Cell Modulation
Animal Models of Neuroinflammation
VIP and Cytokine Modulation
VIP and Other Neuropeptide Modulators
Open Research Questions
Conclusion
Related Research Articles
Explore Related Products
Frequently Asked Questions
Glossary

VIP neuroinflammation research has produced one of the most active areas of preclinical literature on neuropeptide modulation of central nervous system inflammation. Vasoactive intestinal peptide has been characterized in multiple research models for its anti-inflammatory and immunomodulatory effects, particularly in contexts involving microglial activation, T cell signaling, and the broader inflammatory response in the brain. As the neuroinflammation component of the VIP research cluster, this article reviews the published animal model literature on VIP effects on neuroinflammation endpoints, the mechanisms involved, and the broader context for understanding VIP as a research tool in inflammation studies.

Frequently Asked Questions

What is VIP in research contexts?

VIP (vasoactive intestinal peptide) is an endogenous 28-amino-acid neuropeptide of the secretin/glucagon superfamily. It is studied in preclinical models for vasodilation, immune modulation, circadian rhythm regulation, and pulmonary smooth muscle research through VPAC1 and VPAC2 receptor signaling.

How does VIP modulate neuroinflammation?

VIP acts on VPAC1 receptors expressed on microglia and infiltrating T cells in the CNS, reducing pro-inflammatory cytokine production, modulating microglial activation, and supporting neuroprotection in models of brain inflammation, neurodegeneration, and CNS injury.

What neuroinflammation models are used with VIP?

Models include EAE for multiple sclerosis, LPS-induced neuroinflammation, ischemic stroke, traumatic brain injury, and Alzheimer model neuroinflammation. Endpoints span microglial activation, cytokine profiles, T cell infiltration, and behavioral neurological outcomes.

Is VIP approved for human use?

Glossary

Key terms used in this article.

VPAC1: Vasoactive intestinal peptide receptor 1, broadly distributed, mediating immune and gastrointestinal effects of VIP.
VPAC2: Vasoactive intestinal peptide receptor 2, enriched in the suprachiasmatic nucleus and lung, involved in circadian and pulmonary signaling.
Suprachiasmatic Nucleus (SCN): The hypothalamic master circadian pacemaker, where VPAC2 signaling is essential for synchronizing rhythmic neuronal activity.
Vasodilation: Widening of blood vessels resulting from relaxation of vascular smooth muscle, often mediated by nitric oxide or VIP signaling.
Neuropeptide: A peptide produced and released by neurons that acts as a signaling molecule in the nervous system.
Microglia: The resident immune cells of the central nervous system, which mediate neuroinflammation and neuroprotection.
Neuroinflammation: Inflammatory responses in the central nervous system involving microglia, astrocytes, and infiltrating immune cells.

More from the Blog

Continue exploring research insights and updates.

Subcutaneous vs Intranasal: Choosing an Administration Route for DSIP, Selank, and Kisspeptin in Research

Subcutaneous vs intranasal administration for CNS-targeted research peptides: how to choose between routes for DSIP, Selank, and Kisspeptin based on molecular size, brain access, pharmacokinetics, and the published literature.

May 5, 2026

Can I Still Buy Compounded Tirzepatide? (2026 Research Context)

FDA restricted compounded tirzepatide for human use when the shortage ended. The Research Use Only research peptide channel for tirzepatide (GLP-2 TZ) operates under entirely separate regulations.

May 5, 2026

For Research Use Only. VIP is intended exclusively for in vitro and preclinical research. It is not approved for human use, is not a drug, and should never be administered to humans or to animals outside of an authorized research protocol.

Neuroinflammation as a Research Endpoint

Neuroinflammation refers to the inflammatory response within the central nervous system, involving microglia (the resident immune cells of the brain), astrocytes, infiltrating peripheral immune cells, and the production of inflammatory mediators including cytokines, chemokines, and reactive species. Neuroinflammation is a normal physiological response to injury or infection in the brain, but excessive or chronic neuroinflammation is implicated in many research models of neurological disease.

In animal research models, neuroinflammation is typically characterized through measurements of inflammatory cytokines (such as tumor necrosis factor alpha, interleukin-1 beta, interleukin-6), microglial activation markers, immune cell infiltration, and behavioral or functional endpoints that reflect the broader inflammatory state. These methods together provide a comprehensive picture of how an intervention affects neuroinflammation in research models.

VIP research has used these endpoints to characterize its anti-inflammatory effects in rodent and other animal models of neuroinflammation. The published findings consistently support a role for VIP in modulating inflammatory responses in the central nervous system, with the magnitude of the effect depending on the specific experimental conditions and the inflammation model studied.

VIP Effects on Microglia

Microglia are the resident immune cells of the brain and are major contributors to neuroinflammation in research models. Activated microglia produce inflammatory cytokines, reactive oxygen and nitrogen species, and other mediators that contribute to inflammatory damage in central nervous system tissue. The modulation of microglial activation is one of the central topics in neuroinflammation research, and VIP has been studied for its effects on microglial activation in research models.

The published research on VIP and microglia generally supports anti-inflammatory effects, with VIP administration being associated with reduced microglial activation markers, reduced production of inflammatory cytokines from microglia, and shifts in microglial phenotype from pro-inflammatory to more reparative profiles in research models. The mechanism involves VPAC receptor activation on microglia, with downstream signaling that modulates the inflammatory response of these cells.

For more on the receptor biology that underlies these effects, see our companion article on VIP receptor research and VPAC1/VPAC2 signaling in research models.

VIP and T Cell Modulation

T cells are another major component of the inflammatory response in research models, and they can contribute to neuroinflammation through infiltration of central nervous system tissue and through paracrine signaling that affects resident brain cells. VIP has been studied for its effects on T cell function in research models, with the published findings supporting modulation of T cell responses through VPAC receptor activation on these cells.

The T cell effects of VIP include modulation of T helper cell differentiation, with shifts toward regulatory T cell phenotypes that have anti-inflammatory characteristics in research models. The mechanism involves VPAC receptor signaling on T cells, with downstream effects on transcription factors and cytokine production that determine T cell phenotype. These effects have been characterized in cell culture systems and in animal models of inflammation.

The combined effects of VIP on microglia and on T cells produce a coordinated anti-inflammatory profile in research models, addressing both the central nervous system component (microglia) and the peripheral immune component (T cells) of neuroinflammation.

Animal Models of Neuroinflammation

Several rodent models are commonly used in neuroinflammation research, and VIP has been studied in many of these. Standard models include lipopolysaccharide (LPS) induced neuroinflammation, experimental autoimmune encephalomyelitis (EAE) as a research model of multiple sclerosis-like neuroinflammation, models of neurodegeneration with inflammatory components, and various other inflammation protocols.

The published findings on VIP across these different research models generally support its anti-inflammatory effects, although the magnitude and specific endpoints affected vary with the model. The convergence of findings across multiple inflammation models supports the conclusion that VIP modulates neuroinflammation through fundamental mechanisms involving VPAC receptor activation rather than through model-specific effects.

These animal models have also been used to characterize the time course of VIP anti-inflammatory effects, the dose dependence of the response, and the specific cellular mechanisms involved in different inflammation contexts. The combined research provides a substantial preclinical evidence base on VIP as a research tool for neuroinflammation studies.

VIP and Cytokine Modulation

Cytokine measurements are one of the most common endpoints in VIP neuroinflammation research. Studies have examined VIP effects on the production of inflammatory cytokines in cultured microglia, in brain tissue from animal models of neuroinflammation, and in plasma from research animals receiving inflammation challenges. The published findings consistently show reductions in the production of inflammatory cytokines following VIP administration, with the effect being mediated by VPAC receptor activation.

The specific cytokines affected include tumor necrosis factor alpha, interleukin-1 beta, interleukin-6, and other inflammatory mediators that contribute to neuroinflammation in research models. The reductions are typically dose dependent and observed across multiple cell types and tissue sources, supporting a fundamental anti-inflammatory mechanism rather than effects specific to particular cellular contexts.

In addition to reducing pro-inflammatory cytokines, VIP has been associated with increased production of anti-inflammatory cytokines such as interleukin-10 in some research models. This dual effect (reducing pro-inflammatory and increasing anti-inflammatory mediators) provides a coordinated shift in the cytokine profile that characterizes the anti-inflammatory effects of VIP in research.

VIP and Other Neuropeptide Modulators

VIP is one of several neuropeptides that have been characterized as anti-inflammatory modulators in research models. Other peptides in this category include PACAP (which shares much of the receptor binding profile with VIP), alpha-MSH and its C-terminal fragments, and various other peptides that have been studied for immunomodulatory effects.

The relationships between these peptides provide context for understanding VIP within the broader neuropeptide research landscape. PACAP has particularly close functional overlap with VIP because they share the VPAC1 and VPAC2 receptors, meaning that anti-inflammatory effects mediated by VPAC activation can be produced by either peptide in research models. This shared receptor signaling is one of the more important practical considerations for researchers selecting peptides for neuroinflammation studies.

Open Research Questions

Several open research questions remain in the VIP neuroinflammation literature. These include how the anti-inflammatory effects of VIP vary across different neuroinflammation models and conditions, how the relative contributions of VPAC1 and VPAC2 to the anti-inflammatory profile vary across cell types, and how VIP signaling interacts with other anti-inflammatory pathways in research models. Each of these is a legitimate research opportunity for investigators studying neuropeptide modulation of inflammation.

Conclusion

VIP neuroinflammation research provides a substantial body of preclinical evidence on neuropeptide modulation of central nervous system inflammation. The convergent findings on microglial modulation, T cell effects, cytokine reductions, and improvements in standardized neuroinflammation models support the use of VIP as a research tool for studies of inflammation in the brain. For investigators using VIP 10mg as a research tool, the neuroinflammation literature provides essential context for experimental design.

For more on the full VIP research cluster, see the pillar overview article and the supporting articles on each major topic.

VIP is supplied by Midwest Peptide for research use only and is not intended for human administration.

Explore more peer-reviewed research and laboratory guides from our science team:

All products are third-party tested with a Certificate of Analysis (COA) included. For research use only.

VIP 10mg, 99%+ purity, COA included
Selank 10mg, 99%+ purity, COA included
Semax 10mg, 99%+ purity, COA included

Browse All Research Peptides →

Age Verification

VIP Neuroinflammation Research: Animal Model Studies